Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Please go ahead. Thank you, Jason. Good afternoon and welcome to Tempus' Fourth Quarter 2024 Conference Call. This afternoon Tempus released results for the quarter and year ended December 31 ...

16:52 EST Tempus AI (TEM) down 7% at $64.83 after Q4 earnings miss and guidance See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

These speculations have surged in the past month after her investment in AI healthcare firm Tempus AI (NASDAQ:TEM) surged over 300% since 14th January. According to the latest periodic transaction ...

Institutional Interest in Tempus is Still Strong At the end of 2024, Cathie Wood’s ARK Invest increased its stake in TEM by 132% by adding 3.14 million shares. Jane Street Group raised its stake ...

Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom ...

Tempus AI (NASDAQ: TEM) is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI’s stock price has seen an increase, with gains of over 160% in the ...